GlassScriptPhysician profile
Dharam R Anand
NPI 1134107170
$11,458.93
in general payments reported to CMS, 2019-2025
55 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $1,543 · 2021: $2,253 · 2022: $2,226 · 2023: $1,548 · 2024: $1,464 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,588.90 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,608.42 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Nestle Healthcare Nutrition INC. | $1,234.73 | 2020-2023 | |
| Novo Nordisk INC | $1,048.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $673.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $604.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $520.89 | 2019-2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $520.38 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $485.36 | 2019-2025 | Austedo Xr, Austedo |
| Amgen INC. | $402.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.03 | 2020-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $325.24 | 2024-2025 | Zenpep |
| Sunovion Pharmaceuticals INC. | $236.28 | 2021-2022 | |
| Glaxosmithkline, LLC. | $224.22 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $215.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.68 | 2020-2025 | Ofev, Jardiance |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharam Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.